Become A Featured Company

Beckley Psytech appoints leading experts to Scientific Advisory Board

Ryan Allway

November 5th, 2020

Psychedelics

Beckley Psytech, the psychedelic medicine company, has appointed Joanna Neill, Professor of Psychopharmacology at the University of Manchester, and Dr Mike Emanuel, former Vice President of Global Clinical Operations at Johnson & Johnson, to its Scientific Advisory Board.

As members of the Scientific Advisory Board, Neill and Emanuel will channel their expertise to guide and advise Beckley Psytech on its mission to develop a pipeline of psychedelic drugs into licensed pharmaceutical medicines for treating debilitating psychiatric and neurological diseases.

Neill is Professor of Psychopharmacology at the University of Manchester (Division of Pharmacy & Optometry). She is Chair of the Medical Psychedelics Working Group for Drug Science, a scientific advisor for Heroic Hearts UK and the Conservative Drug Policy Reform Group. She is also co-founder of b-neuro, a University based Contract Research Organisation developing new treatments for mental illness through animal models. Dr Emanuel brings extensive experience in the pharmaceutical industry including a long career at Johnson & Johnson, where he was vice president of global clinical operations for EMEA, leading a team of over 400 clinical research professionals operating in 27 countries. He has also held roles including as a board member of Janssen-Cilag International and as an associate director of the National Institute for Health Research’s Clinical Research Network.

Beckley Psytech’s Scientific Advisory Board comprises a panel of the world’s leading psychedelic and psychiatric researchers, policy experts and drug development specialists, including:

  • Professor Guy Goodwin, Senior Research Fellow at the Department of Psychiatry, The University of Oxford
  • Dr Robin L. Carhart-Harris PhD, Director of the Centre for Psychedelic Research at Imperial College London
  • Professor Matthew W. Johnson PhD, Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine
  • Frederick Reinholdt MA, Senior Therapist in Psychedelics at The Institute of Psychiatry, Psychology and Neuroscience, King’s College London
  • Lady Amanda Feilding, Beckley Psytech co-founder, Beckley Foundation founder and chair of the Scientific Advisory Board

Commenting on her appointment, Professor Joanna Neill, University of Manchester, says:“Beckley Psytech is doing vital work to deliver psychedelic medicines with transformative potential for treating mental health disorders. I am very excited to be supporting the company’s mission and will use my experience to advise the team as it pioneers these novel approaches for mainstream medical practice. If successful, the company will create fully licensed medicines to improve the lives of patients suffering from mental health conditions worldwide.”

Dr Mike Emanuel, says: “This is a fascinating area of research and Beckley Psytech have a brilliant team of drug developers who I know well and have worked with in the past. I’m looking forward to helping with the successful delivery and rollout of medicines which can change the face of mental health treatment. The potential for psychedelic drugs to improve health outcomes for patients is huge and I am excited to be working with the company to capitalise on this opportunity.”

Full biographies for the members of the Beckley Psytech Scientific Advisory Board can be found here.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading